-transparent.png){kind=logo}
Due to the increasing pressure to investigate new drugs under conditions met with in practice, Lormetazepam (0.5 mg) was investigated in nine general practices under the direction and collaboration of a psychiatrist used to investigations with psychopharmaceuticals. The results of a double-blind study, carried out in comparison to triazolam (0.5 mg), in a total of 94 ambulatory patients are presented.
Related Publications
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
January 1983,
Clinical therapeutics,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
January 1983,
British journal of clinical pharmacology,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
May 1983,
British journal of clinical pharmacology,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
January 1977,
The Journal of international medical research,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
January 1977,
The Journal of international medical research,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
March 1982,
Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
January 1981,
International journal of clinical pharmacology, therapy, and toxicology,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
June 1966,
The Practitioner,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
July 1986,
Health bulletin,
W Pöldinger, and
M Sastre-y-Hernández, and
K Fichte
February 1966,
Die Medizinische Welt,
